Project Grant 2223225
Award Date 3/15/23
Completion Date 8/31/24
Dollars Obligated $275K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53202, USA
Similar Awards
- This SBIR Phase I Project Grant, valued at $305,000.00 and awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a novel class of peptide-based compounds capable of safely and effectively treating autoimmune and inflammatory disorders, including rare diseases affecting pediatric populations. The project will demonstrate the unique design of these compounds to modulate immune responses from pro- to...
- The National Science Foundation awarded Sarkar-Klein-Labs, LLC a $225,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the STTR PHASE I: PROTEASE-BASED PURIFICATION OF RECOMBINANT HUMAN MATRIX METALLOPROTEASES project. This two-year project beginning February 1, 2021 aims to develop protease-based purification methods for recombinant human matrix metalloproteases, which are enzymes involved in tissue remodeling and disease processes. The...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $999,878 to Akttyva Therapeutics, Inc., a small business located in Watertown, MA, to develop an AI-assisted drug discovery platform to identify existing drugs and new chemical entities capable of repairing vascular permeability barriers. The project aims to address unmet clinical needs for conditions like acute respiratory distress...
- This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is focused on the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The goal is to address the critical health and economic burden associated with implant-related infections by reducing or eliminating them through the use of this biocompatible and antimicrobial nano-biological coating. The $305,000...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
- This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...
- Federal Grant Award Summary Peptiforge, Inc. received a $306,872 Phase 1 Small Business Innovation Research (SBIR) Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2026. The award funds development of a proprietary platform technology designed to accelerate the discovery of protein binders—proteins that selectively bind to specific therapeutic...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $275,000 to Altay Therapeutics, Inc., a biotechnology company, to develop novel small molecule therapies that target disease-causing transcription factors for treating chronic illnesses and cancers. The key goals of this SBIR Phase I project are to: (1) determine the toxicity profile of new inhibitors across human cells, (2) measure drug specificity to the target...